Agilent Completes Acquisition of BIOVECTRA

(Image: Business Wire)

All closing conditions have been satisfied, including receipt of regulatory approvals. BIOVECTRA is now part of Agilent’s Diagnostics and Genomics Group.

“We are excited to officially welcome the BIOVECTRA team to Agilent,” said Agilent President and CEO Padraig McDonnell. “This acquisition demonstrates our commitment to providing customers with the most advanced capabilities to accelerate their therapeutic programs, including best-in-class cGMP pharmaceutical manufacturing.”

With the addition of BIOVECTRA, Agilent will expand its portfolio of CDMO services, add fast-growing modalities, and deliver world-class capabilities to support gene editing. Additional details are available in the press release announcing the acquisition agreement.

Agilent expects the transaction to be $0.05 dilutive to non-GAAP earnings per share (EPS) in the first full year after closing and to produce a double-digit return on invested capital (ROIC) in year five. Agilent financed the transaction with a mix of cash and debt financing.

Additional information
Frequently Asked Questions for Customers
Highlights for investors
About Agilent’s Oligonucleotide GMP Production
About BIOVECTRA

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovations that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers’ most challenging questions. The company generated revenues of $6.83 billion in fiscal year 2023 and employs approximately 18,000 people worldwide. Information about Agilent is available at www.agilent.com. Subscribe to the Agilent Newsroom to receive the latest Agilent news. Follow Agilent on LinkedIn and Facebook.

Diskutieren Sie über die entaltenen Werte